HRP20130973T1 - Farmaceutski pripravci koji sadrže supstituirane derivate piridina - Google Patents
Farmaceutski pripravci koji sadrže supstituirane derivate piridina Download PDFInfo
- Publication number
- HRP20130973T1 HRP20130973T1 HRP20130973TT HRP20130973T HRP20130973T1 HR P20130973 T1 HRP20130973 T1 HR P20130973T1 HR P20130973T T HRP20130973T T HR P20130973TT HR P20130973 T HRP20130973 T HR P20130973T HR P20130973 T1 HRP20130973 T1 HR P20130973T1
- Authority
- HR
- Croatia
- Prior art keywords
- morpholin
- dimethyl
- pyridin
- acetamide
- phenyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 210000003205 muscle Anatomy 0.000 claims 4
- -1 (2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-benzyl ester Chemical class 0.000 claims 2
- FHZUOZWUOXJEHV-UHFFFAOYSA-N (2-chlorophenyl)methyl n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)carbamate Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)OCC1=CC=CC=C1Cl FHZUOZWUOXJEHV-UHFFFAOYSA-N 0.000 claims 1
- CKYXLLATWNDTOC-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=C(Cl)C(Cl)=C1 CKYXLLATWNDTOC-UHFFFAOYSA-N 0.000 claims 1
- XBRHVWUAWYACKQ-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=C(F)C(F)=C1 XBRHVWUAWYACKQ-UHFFFAOYSA-N 0.000 claims 1
- AQBIYGJLUAYHKV-UHFFFAOYSA-N 2-(3-bicyclo[2.2.1]heptanyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound N=1C(C)=C(NC(=O)CC2C3CCC(C3)C2)C(C)=CC=1N1CCOCC1 AQBIYGJLUAYHKV-UHFFFAOYSA-N 0.000 claims 1
- LTYGQAJETYOFCA-UHFFFAOYSA-N 2-(3-bromophenyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CC(Br)=C1 LTYGQAJETYOFCA-UHFFFAOYSA-N 0.000 claims 1
- IWPAOTPPULTUIR-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CC(Cl)=C1 IWPAOTPPULTUIR-UHFFFAOYSA-N 0.000 claims 1
- QKKSRAZNRMRSGA-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=C(Cl)C=C1 QKKSRAZNRMRSGA-UHFFFAOYSA-N 0.000 claims 1
- MEPMQOPXUQHOJD-UHFFFAOYSA-N 2-(cyclohexen-1-yl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CCCCC1 MEPMQOPXUQHOJD-UHFFFAOYSA-N 0.000 claims 1
- ZWODLPCPFZMMPF-UHFFFAOYSA-N 2-cyclopentyl-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1CCCC1 ZWODLPCPFZMMPF-UHFFFAOYSA-N 0.000 claims 1
- OESDYULIRWTQIK-UHFFFAOYSA-N 3-(3-chlorophenyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)propanamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CCC1=CC=CC(Cl)=C1 OESDYULIRWTQIK-UHFFFAOYSA-N 0.000 claims 1
- PVKGAFIBJUZLPW-UHFFFAOYSA-N 3-cyclohexyl-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)propanamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CCC1CCCCC1 PVKGAFIBJUZLPW-UHFFFAOYSA-N 0.000 claims 1
- WHTGDXHISJRNKN-UHFFFAOYSA-N 3-cyclopentyl-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)propanamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CCC1CCCC1 WHTGDXHISJRNKN-UHFFFAOYSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- NSXYSIRPQHZGRS-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(3,4-dimethylphenyl)acetamide Chemical compound C1=C(C)C(C)=CC=C1CC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C NSXYSIRPQHZGRS-UHFFFAOYSA-N 0.000 claims 1
- QFXOZVHCESXJLE-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(3,5-dimethylphenyl)acetamide Chemical compound CC1=CC(C)=CC(CC(=O)NC=2C(=NC(=CC=2C)N2CCOCC2)C)=C1 QFXOZVHCESXJLE-UHFFFAOYSA-N 0.000 claims 1
- LNHWKNMHQDEDHA-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(3-fluorophenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CC(F)=C1 LNHWKNMHQDEDHA-UHFFFAOYSA-N 0.000 claims 1
- MTXSFPSKHDODED-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(CC(=O)NC=2C(=NC(=CC=2C)N2CCOCC2)C)=C1 MTXSFPSKHDODED-UHFFFAOYSA-N 0.000 claims 1
- LXXQJPDIABMXEO-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(4-fluorophenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=C(F)C=C1 LXXQJPDIABMXEO-UHFFFAOYSA-N 0.000 claims 1
- RVOCAYGOJGYTFK-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(4-methoxy-3-methylphenyl)acetamide Chemical compound C1=C(C)C(OC)=CC=C1CC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C RVOCAYGOJGYTFK-UHFFFAOYSA-N 0.000 claims 1
- ZWAWWLRQLGIARH-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C ZWAWWLRQLGIARH-UHFFFAOYSA-N 0.000 claims 1
- ZZQZQXDYSRXASP-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(4-methylphenyl)acetamide Chemical compound C1=CC(C)=CC=C1CC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C ZZQZQXDYSRXASP-UHFFFAOYSA-N 0.000 claims 1
- OEMGVWLOWRPQLL-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1 OEMGVWLOWRPQLL-UHFFFAOYSA-N 0.000 claims 1
- GKDVUJSUFGQXKA-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-naphthalen-2-ylacetamide Chemical compound N=1C(C)=C(NC(=O)CC=2C=C3C=CC=CC3=CC=2)C(C)=CC=1N1CCOCC1 GKDVUJSUFGQXKA-UHFFFAOYSA-N 0.000 claims 1
- LOCRXXVELNBLQE-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-phenylacetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CC=C1 LOCRXXVELNBLQE-UHFFFAOYSA-N 0.000 claims 1
- MRNPWIWBKMYBTH-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-phenylcyclopropane-1-carboxamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)C1CC1C1=CC=CC=C1 MRNPWIWBKMYBTH-UHFFFAOYSA-N 0.000 claims 1
- VRDZAGWZCGIZSC-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-thiophen-2-ylacetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CS1 VRDZAGWZCGIZSC-UHFFFAOYSA-N 0.000 claims 1
- ZBQQCPVAXQILBE-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-thiophen-3-ylacetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC=1C=CSC=1 ZBQQCPVAXQILBE-UHFFFAOYSA-N 0.000 claims 1
- BKFDFCVASNKPOA-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CCOCC2)=N1 BKFDFCVASNKPOA-UHFFFAOYSA-N 0.000 claims 1
- WVSKXMHDWLIKIR-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-3,5,5-trimethylhexanamide Chemical compound N1=C(C)C(NC(=O)CC(C)CC(C)(C)C)=C(C)C=C1N1CCOCC1 WVSKXMHDWLIKIR-UHFFFAOYSA-N 0.000 claims 1
- KAKNMOGUWPXQFL-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-3-(4-methoxyphenyl)propanamide Chemical compound C1=CC(OC)=CC=C1CCC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C KAKNMOGUWPXQFL-UHFFFAOYSA-N 0.000 claims 1
- OFNMXZJAGVKVKO-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-3-(4-methylphenyl)propanamide Chemical compound C1=CC(C)=CC=C1CCC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C OFNMXZJAGVKVKO-UHFFFAOYSA-N 0.000 claims 1
- BLESCNKLEXGCBO-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-4-methylpentanamide Chemical compound N1=C(C)C(NC(=O)CCC(C)C)=C(C)C=C1N1CCOCC1 BLESCNKLEXGCBO-UHFFFAOYSA-N 0.000 claims 1
- LRPPLNWCCXUMIQ-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-5-methylhexanamide Chemical compound N1=C(C)C(NC(=O)CCCC(C)C)=C(C)C=C1N1CCOCC1 LRPPLNWCCXUMIQ-UHFFFAOYSA-N 0.000 claims 1
- RZPBJOUKSLGPAK-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)heptanamide Chemical compound N1=C(C)C(NC(=O)CCCCCC)=C(C)C=C1N1CCOCC1 RZPBJOUKSLGPAK-UHFFFAOYSA-N 0.000 claims 1
- SAHHONAYVKIMTP-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)hexanamide Chemical compound N1=C(C)C(NC(=O)CCCCC)=C(C)C=C1N1CCOCC1 SAHHONAYVKIMTP-UHFFFAOYSA-N 0.000 claims 1
- QHRDANBBSJKUAT-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)octanamide Chemical compound N1=C(C)C(NC(=O)CCCCCCC)=C(C)C=C1N1CCOCC1 QHRDANBBSJKUAT-UHFFFAOYSA-N 0.000 claims 1
- JXZMYIPYHBOYME-UHFFFAOYSA-N n-(2-chloro-4-methoxy-6-morpholin-4-ylpyridin-3-yl)-2-cyclopentylacetamide Chemical compound COC1=CC(N2CCOCC2)=NC(Cl)=C1NC(=O)CC1CCCC1 JXZMYIPYHBOYME-UHFFFAOYSA-N 0.000 claims 1
- PWTTZEIOVBSDKM-UHFFFAOYSA-N n-(2-chloro-4-methoxy-6-morpholin-4-ylpyridin-3-yl)-3,3-dimethylbutanamide Chemical compound ClC1=C(NC(=O)CC(C)(C)C)C(OC)=CC(N2CCOCC2)=N1 PWTTZEIOVBSDKM-UHFFFAOYSA-N 0.000 claims 1
- CTONPIFXRWAMMT-UHFFFAOYSA-N n-(4-chloro-2-methoxy-6-morpholin-4-ylpyridin-3-yl)-2-cyclopentylacetamide Chemical compound COC1=NC(N2CCOCC2)=CC(Cl)=C1NC(=O)CC1CCCC1 CTONPIFXRWAMMT-UHFFFAOYSA-N 0.000 claims 1
- OSHLKYWGTPRHND-UHFFFAOYSA-N n-(4-chloro-2-methoxy-6-morpholin-4-ylpyridin-3-yl)-3,3-dimethylbutanamide Chemical compound ClC1=C(NC(=O)CC(C)(C)C)C(OC)=NC(N2CCOCC2)=C1 OSHLKYWGTPRHND-UHFFFAOYSA-N 0.000 claims 1
- FNGCWQBVWMPXRW-UHFFFAOYSA-N n-(4-chloro-2-methoxy-6-morpholin-4-ylpyridin-3-yl)propanamide Chemical compound N1=C(OC)C(NC(=O)CC)=C(Cl)C=C1N1CCOCC1 FNGCWQBVWMPXRW-UHFFFAOYSA-N 0.000 claims 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (5)
1. Farmaceutski pripravak za primjenu u mišić koji sadrži spoj izabran iz grupe koja obuhvaća (2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-benzilni ester karbaminske kiseline; (2,4-Dimetil-6-morfolin-4-ilpiridin-3-il)-karbaminska kiselina 2-kloro-benzil ester; 2-(4-Kloro-fenil)-N-(2,4-dimetil-6-morfolin-4-ilpiridin-3-il)-acetamid; 2-Fenil-ciklopropankarboksilna kiselina (2,4-dimetil-6-morfolin-4-il-piridin-3-il)-amid; N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-tiofen-2-il-acetamid; 3-Cikloheksil-N-(2,4-dimetil-6-morfolin-4-il-piridin-3-il)-propionamid; (2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-izobutilni ester karbaminske kiseline; 3-(3-Kloro-fenil)-N-(2,4-dimetil-6-morfolin-4-il-piridin-3-il)-propionamid; N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-(3,5-dimetil-fenil)-acetamid; i N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-3-p-tolil-propionamid; ili njegovu farmaceutski prihvatljivu sol.
2. Farmaceutski pripravak za primjenu u mišić koji sadrži spoj izabran iz grupe koja obuhvaća 2-(3-Kloro-fenil)-N-(2,4-dimetil-6-morfolin-4-il-piridin-3-il)-acetamid; 2-(3,4-Dikloro-fenil)-N-(2,4-dimetil-6-morfolin-4-il-piridin-3-il)-acetamid; N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-tiofen-3-il-acetamid; N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-p-tolil-acetamid; 2-(3-Bromo-fenil)-N-(2,4-dimetil-6-morfolin-4-il-piridin-3-il)-acetamid; N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-(3-trifluorometil-fenil)-acetamid; N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-fenil-acetamid; 3,5,5-Trimetil-heksan kiselina (2,4-dimetil-6-morfolin-4-il-piridin-3-il)-amid; i Oktan kiselina (2,4-dimetil-6-morfolin-4-il-piridin-3-il)-amid ili njegovu farmaceutski prihvatljivu sol.
3. Farmaceutski pripravak za primjenu u mišić koji sadrži spoj izabran iz grupe koja obuhvaća N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-naftalen-2-il-acetamid; Heptan kiselina (2,4-dimetil-6-morfolin-4-il-piridin-3-il)-amid; N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-(3,4-dimetil-fenil)-acetamid; 2-(Cikloheks-1-enil)-N-(2,4-dimetil-6-morfolin-4-il-piridin-3-il)-acetamid; N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-(4-metoksi-3-metil-fenil)-acetamid; N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-(4-metoksi-fenil)-acetamid; N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-3-(4-metoksi-fenil)-propionamid; N-(2,4-Dimetil-6-morfolin-4-ilpiridin-3-il)-2-m-tolil-acetamid; i N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-(4-fluoro-fenil)-acetamid; ili njegovu farmaceutski prihvatljivu sol.
4. Farmaceutski pripravak za primjenu u mišić koji sadrži spoj izabran iz grupe koja obuhvaća N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-3,3-dimetil-butiramid; N-(2,4-Dimetil-6-morfolin-4-il-piridin-3-il)-2-(3-fluoro-fenil)-acetamid; 2-Biciklo[2.2.1]hept-2-il-N-(2,4-dimetil-6-morfolin-4-il-piridin-3-il)-acetamid; 2-(3,4-Difluoro-fenil)-N-(2,4-dimetil-6-morfolin-4-ilpiridin-3-il)-acetamid; i 4-Metil-pentan kiselina (2,4-dimetil-6-morfolin-4-il-piridin-3-il)-amid; ili njegovu farmaceutski prihvatljivu sol.
5. Farmaceutski pripravak za primjenu u mišić koji sadrži spoj izabran iz grupe koja obuhvaća 5-Metil-heksan kiselina (2,4-dimetil-6-morfolin-4-il-piridin-3-il)-amid; 2-Ciklopentil-N-(2,4-dimetil-6-morfolin-4-il-piridin-3-il)-acetamid; 3-Ciklopentil-N-(2, 4-dimetil-6-morfolin-4-il-piridin-3-il)-propionamid; Heksan kiselina (2, 4-dimetil-6-morfolin-4-il-piridin-3-il)-amid; N-(4-Kloro-2-metoksi-6-morfolin-4-il-piridin-3-il)-2-ciklopentilacetamid; N-(2-Kloro-4-metoksi-6-morfolin-4-il-piridin-3-il)-2-ciklopentilacetamid; N-(2-Kloro-4-metoksi-6-morfolin-4-il-piridin-3-il)-3, 3-dimetilbutiramid; N-(4-Kloro-2-metoksi-6-morfolin-4-il-piridin-3-il)-3,3-dimetilbutiramid; i N-(4-Kloro-2-metoksi-6-morfolin-4-il-piridin-3-il)-propionamid; ili njegovu farmaceutski prihvatljivu sol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65842805P | 2005-03-03 | 2005-03-03 | |
| DKPA200500321 | 2005-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130973T1 true HRP20130973T1 (hr) | 2013-11-22 |
Family
ID=36544250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130973TT HRP20130973T1 (hr) | 2005-03-03 | 2013-10-14 | Farmaceutski pripravci koji sadrže supstituirane derivate piridina |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7812020B2 (hr) |
| EP (2) | EP1861394A1 (hr) |
| JP (2) | JP5237643B2 (hr) |
| AU (1) | AU2006220130B2 (hr) |
| CA (1) | CA2599890C (hr) |
| CY (1) | CY1114561T1 (hr) |
| HR (1) | HRP20130973T1 (hr) |
| MX (1) | MX2007010547A (hr) |
| NO (1) | NO20074959L (hr) |
| PL (1) | PL2298766T3 (hr) |
| WO (1) | WO2006092143A1 (hr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7799832B2 (en) | 2003-10-23 | 2010-09-21 | Valeant Pharmaceuticals North America | Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| EP1861394A1 (en) * | 2005-03-03 | 2007-12-05 | H.Lundbeck A/S | Substituted pyridine derivatives |
| US20070078177A1 (en) * | 2005-09-30 | 2007-04-05 | Washington University In St. Louis | Methods and compositions for treating non age related hearing impairment in a subject |
| TWI453013B (zh) * | 2006-02-07 | 2014-09-21 | Lundbeck & Co As H | N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品 |
| US7960436B2 (en) | 2006-06-05 | 2011-06-14 | Valeant Pharmaceuticals International | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators |
| CA2661462C (en) | 2006-08-23 | 2015-09-29 | Valeant Pharmaceuticals International | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| US8993593B2 (en) | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| MX2009005652A (es) | 2006-11-28 | 2009-08-07 | Valeant Pharmaceuticals Int | Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio. |
| US8367684B2 (en) | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| US20100256145A1 (en) * | 2007-08-01 | 2010-10-07 | H. Lundbeck A/S | Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
| US7786146B2 (en) | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
| WO2010094644A1 (en) | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
| WO2010094645A1 (en) | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
| WO2010097379A1 (en) | 2009-02-24 | 2010-09-02 | Neurosearch A/S | Substituted pyrimidin derivatives and their medical use |
| TWI504395B (zh) | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
| TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| TW201038565A (en) * | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
| TWI461197B (zh) | 2009-03-12 | 2014-11-21 | 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier | |
| US20120238547A1 (en) | 2009-09-07 | 2012-09-20 | Neurosearch A/S | 2, 3, 6 - triamino substituted pyridines as kv7 (kcnq) channel modulators |
| WO2011026891A1 (en) | 2009-09-07 | 2011-03-10 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
| NZ604745A (en) | 2010-08-27 | 2015-01-30 | Gruenenthal Chemie | Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators |
| US8470852B2 (en) | 2010-08-27 | 2013-06-25 | Gruenenthal Gmbh | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators |
| EP2609086B1 (en) | 2010-08-27 | 2015-02-25 | Grünenthal GmbH | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators |
| MX2013002295A (es) | 2010-09-01 | 2013-05-09 | Gruenenthal Gmbh | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. |
| KR101820645B1 (ko) * | 2010-10-20 | 2018-01-22 | 그뤼넨탈 게엠베하 | Ｋｃｎｑ２／３ 조절제로서의 치환된 ６아미노니코틴아미드 |
| AU2015201122B2 (en) * | 2010-10-20 | 2016-02-25 | Grunenthal Gmbh | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators |
| US9168259B2 (en) * | 2010-10-20 | 2015-10-27 | Grünenthal GmbH | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators |
| CA2839350A1 (en) | 2011-07-05 | 2013-01-10 | Contera Pharma Aps | The use of serotonin receptor agonists for treatment of movement disorders |
| AU2013248638A1 (en) | 2012-04-18 | 2014-12-04 | Grünenthal GmbH | Substituted 4-aminobenzamides as KCNQ2/3 modulators |
| CA2950469C (en) | 2014-06-26 | 2022-09-20 | Contera Pharma Aps | Use of buspirone metabolites |
| JP7100125B2 (ja) * | 2017-10-27 | 2022-07-12 | フレゼニウス・カビ・オンコロジー・リミテッド | リボシクリブおよびその塩の改善された調製のためのプロセス |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4200259A1 (de) | 1992-01-08 | 1993-07-15 | Asta Medica Ag | Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung |
| WO1996021644A1 (en) * | 1995-01-10 | 1996-07-18 | Smithkline Beecham S.P.A. | Indole derivatives useful in the treatment of osteoporosis |
| DE19539861A1 (de) | 1995-10-26 | 1997-04-30 | Asta Medica Ag | Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen |
| EP1033366A3 (en) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Amide derivatives useful as Neuropeptide Y (NPY) antagonists |
| US6407120B1 (en) | 1999-02-18 | 2002-06-18 | Pfizer Inc. | Neuropeptide Y antagonists |
| DE60037321T4 (de) * | 1999-08-04 | 2010-01-07 | Icagen, Inc. | Benzanilide als öffner des kaliumkanals |
| US6495550B2 (en) * | 1999-08-04 | 2002-12-17 | Icagen, Inc. | Pyridine-substituted benzanilides as potassium ion channel openers |
| US6117900A (en) | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
| WO2001092526A1 (en) | 2000-05-26 | 2001-12-06 | Bristol-Myers Squibb Company | Human kcnq5 potassium channel, methods and compositions thereof |
| WO2001096540A2 (en) | 2000-06-11 | 2001-12-20 | Dupont Pharmaceuticals Company | Hepatitis c protease exosite for inhibitor design |
| US6589986B2 (en) | 2000-12-20 | 2003-07-08 | Wyeth | Methods of treating anxiety disorders |
| EP1361879A1 (en) * | 2001-02-20 | 2003-11-19 | Bristol-Myers Squibb Company | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
| JP2003206230A (ja) * | 2002-01-10 | 2003-07-22 | Yamanouchi Pharmaceut Co Ltd | シアノヘテロ環誘導体又はその塩 |
| US7906537B2 (en) | 2003-03-21 | 2011-03-15 | H. Lundbeck A/S | Substituted p-diaminobenzene derivatives |
| TWI357901B (en) | 2004-03-12 | 2012-02-11 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivati |
| EP1861394A1 (en) * | 2005-03-03 | 2007-12-05 | H.Lundbeck A/S | Substituted pyridine derivatives |
-
2006
- 2006-03-02 EP EP06706094A patent/EP1861394A1/en not_active Withdrawn
- 2006-03-02 EP EP10182072.8A patent/EP2298766B1/en active Active
- 2006-03-02 CA CA2599890A patent/CA2599890C/en not_active Expired - Fee Related
- 2006-03-02 PL PL10182072T patent/PL2298766T3/pl unknown
- 2006-03-02 JP JP2007557330A patent/JP5237643B2/ja not_active Expired - Fee Related
- 2006-03-02 AU AU2006220130A patent/AU2006220130B2/en not_active Ceased
- 2006-03-02 MX MX2007010547A patent/MX2007010547A/es active IP Right Grant
- 2006-03-02 US US11/817,340 patent/US7812020B2/en not_active Expired - Fee Related
- 2006-03-02 WO PCT/DK2006/000123 patent/WO2006092143A1/en active Application Filing
-
2007
- 2007-10-02 NO NO20074959A patent/NO20074959L/no not_active Application Discontinuation
-
2010
- 2010-09-14 US US12/881,263 patent/US8299071B2/en not_active Expired - Fee Related
-
2013
- 2013-02-26 JP JP2013036417A patent/JP5705249B2/ja not_active Expired - Fee Related
- 2013-10-14 HR HRP20130973TT patent/HRP20130973T1/hr unknown
- 2013-10-25 CY CY20131100948T patent/CY1114561T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7812020B2 (en) | 2010-10-12 |
| CY1114561T1 (el) | 2016-10-05 |
| US20110003811A1 (en) | 2011-01-06 |
| AU2006220130B2 (en) | 2011-07-28 |
| JP2008531609A (ja) | 2008-08-14 |
| PL2298766T3 (pl) | 2014-09-30 |
| JP5237643B2 (ja) | 2013-07-17 |
| EP2298766A1 (en) | 2011-03-23 |
| CA2599890C (en) | 2011-05-03 |
| JP5705249B2 (ja) | 2015-04-22 |
| AU2006220130A1 (en) | 2006-09-08 |
| EP2298766B1 (en) | 2013-09-18 |
| EP1861394A1 (en) | 2007-12-05 |
| WO2006092143A1 (en) | 2006-09-08 |
| US8299071B2 (en) | 2012-10-30 |
| US20080318953A1 (en) | 2008-12-25 |
| MX2007010547A (es) | 2007-10-03 |
| CA2599890A1 (en) | 2006-09-08 |
| NO20074959L (no) | 2007-10-02 |
| JP2013136613A (ja) | 2013-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130973T1 (hr) | Farmaceutski pripravci koji sadrže supstituirane derivate piridina | |
| HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
| WO2007030777A3 (en) | Amide and carbamate derivatives of alkyl substituted n-[4-(4-amino-1h-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamides and methods | |
| ES2548878T3 (es) | Métodos de tratamiento de úlceras de la piel | |
| JP2007528880A5 (hr) | ||
| HRP20020158B1 (hr) | Kombinacije sinergističnog djelovanja | |
| AR054445A1 (es) | Formulaciones de un inhibidor de src/abl | |
| RS54707B1 (en) | TREATMENT OF CROWN LAKVINIMOD DISEASE | |
| HRP20140214T1 (hr) | Derivati tetrahidrokinolina za lijeäśenje posttraumatskog stresnog poremeä†aja | |
| EP1715853A4 (en) | COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF | |
| MEP33708A (hr) | Farmaceutske smješe koje obuhvataju inhibitor hmg coa reduktaze | |
| RS51464B (en) | BETA-2 ADRENOCEPTOR AGONISTS FOR TREATMENT OF DISEASES OF THE SKIN TISSUE TISSUE | |
| EP4306113A3 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| RU2009148507A (ru) | Производное тетрагидроизохинолин-1-она или его соль | |
| IL288302A (en) | Pharmaceutical preparations including fxr agonist and fibrate for use in the treatment of cholestatic liver disease | |
| MA27731A1 (fr) | Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete | |
| DOP2005000085A (es) | Composicion farmaceutica antimicobacterial | |
| EA200801614A1 (ru) | Фармацевтическая композиция, содержащая монтелукаст | |
| SE9903995D0 (sv) | New combination | |
| MA53099A (fr) | Formes d'ivosidénib et compositions pharmaceutiques | |
| SG11202107439XA (en) | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same | |
| WO2010030201A3 (en) | Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid | |
| SE9902937D0 (sv) | Pharmaceutical compositions | |
| HRP20230693T1 (hr) | Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti | |
| HRP20201262T1 (hr) | Kombinacija inverzivnih agonista histamin-3 receptora sa inhibitorima acetilkolinesteraze |